GSK plc (GSK)
| Market Cap | 74.22B |
| Revenue (ttm) | 37.13B |
| Net Income (ttm) | 19.53B |
| Shares Out | 2.05B |
| EPS (ttm) | 9.21 |
| PE Ratio | 11.81 |
| Forward PE | 9.80 |
| Dividend | $1.45 (3.99%) |
| Ex-Dividend Date | Aug 17, 2023 |
| Volume | 4,184,339 |
| Open | 36.53 |
| Previous Close | 36.34 |
| Day's Range | 36.09 - 36.67 |
| 52-Week Range | 29.38 - 39.74 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 1, 2023 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc a... [Read more]
Financial Performance
In 2022, GSK plc's revenue was 29.32 billion, an increase of 18.74% compared to the previous year's 24.70 billion. Earnings were 14.96 billion, an increase of 241.07%.
Financial numbers in GBP Financial StatementsNews
GSK lifts growth ambitions for HIV business on long-acting drug
GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating...
Explainer: What you need to know about RSV and the new vaccines
Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are meeting on Friday to discuss recommendations for use of the first vaccine for respiratory syncytial virus (RSV) approved for p...
European Commission authorises GSK's HIV prevention drug
The European Commission has authorised GSK's HIV-focused unit ViiV Healthcare's cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.
Incyte shares drop after FDA approves GSK's competing blood-cancer treatment
Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK, +0.11% blood-cancer treatment, Ojjaara, that wil...
US FDA approves GSK's anemia treatment
British drugmaker GSK Plc said on Friday the U.S. Food and Drug Administration had approved its experimental drug to treat anemic patients with a type of bone marrow cancer called myelofibrosis.
EU regulator recommends to stop sale of GSK's blood cancer drug
The European Medicines Agency's human medicines committee on Friday recommended against renewal of the conditional marketing authorisation for GSK's blood cancer drug Blenrep.
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
PHILADELPHIA--(BUSINESS WIRE)--GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations.
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
PHILADELPHIA--(BUSINESS WIRE)-- #AREXVY--GSK announces AREXVY, its respiratory syncytial virus (RSV) vaccine, is now available at all major US retail pharmacies.
Pfizer Sued By GSK Over Alleged Patent Infringement For Its RSV Vaccine
British drugmaker GlaxoSmithKline is accusing Pfizer of infringing on four of its patents in its RSV vaccine.
GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine
Both RSV vaccines were approved by the U.S. Food and Drug Administration for use in adults 60 and above.
GSK sues Pfizer in US for patent infringement over RSV vaccine
British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its riva...
GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
London-based GSK is preparing to roll out its RSV vaccine in the U.S. and European Union this fall, when the disease begins to spread at higher levels.
India's GlaxoSmithKline Pharma posts rise in Q1 profit on steady vaccine business
GlaxoSmithKline Pharmaceuticals , the Indian unit of UK's GSK plc , posted an 11% rise in first-quarter profit on Wednesday, buoyed by strong demand for its vaccines.
GSK expects RSV vaccine uptake will be slower than for its shingles vaccine-CEO
GSK does not expect uptake of its RSV vaccine will initially be as swift as it was for its blockbuster shingles vaccine, though the company is confident in its new inoculation, Chief Executive Emma Wa...
GSK raises 2023 outlook boosted by vaccine, HIV drug sales
GSK raised its full-year profit and sales guidance on Wednesday after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines.
GSK's HIV prevention drug gets European marketing nod
GSK Plc said on Monday that its HIV-focused unit ViiV Healthcare's cabotegravir injected drug and tablets got marketing authorisation from the European Medicines Agency.
GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine
SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG (“LimmaTech Bio”), a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, signed an in-li...
GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for...
Elsie Biotechnologies Announces Collaboration with GSK to Accelerate Oligonucleotide Discovery Technologies
SAN DIEGO--(BUSINESS WIRE)-- #mRNA--Elsie Biotechnologies, Inc., a biopharmaceutical company unlocking the full potential of oligonucleotide therapeutics, announced today a research collaboration agre...
UK regulator authorizes GSK's RSV vaccine
Britain's medicines regulator authorized GSK's vaccine for respiratory syncytial virus (RSV) for older adults, the drugmaker said on Monday.
CDC recommends RSV vaccines from Pfizer, GSK for adults 60 and older
The CDC said the shots from Pfizer and GSK are expected to be available this fall, when RSV – along with Covid and the flu – begins to spread at higher levels.
US CDC recommends use of new Pfizer, GSK vaccines for RSV in older adults
The director of the U.S. Centers for Disease Control and Prevention (CDC) signed off on Thursday on the use of new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infe...
Drugmaker GSK Is Becoming a Healthier Value Stock
Like most stocks during the dot-com bubble, GSK PLC NYSE: GSK partied like it was 1999. In the two decades since, missteps and competitive pressures slashed roughly 50% from the U.K. pharmaceutical co...
GSK's gonorrhoea vaccine receives FDA's 'fast-track' designation
GSK's vaccine candidate to treat sexually transmitted infection gonorrhoea has been granted a fast-track designation by the U.S. Food and Drug Administration (FDA), the British drugmaker said on Tuesd...
GSK Settles Zantac Cancer Lawsuit Set to Go to Trial Next Month
American depositary receipts of GSK jumped after the U.K.-based biopharma company said it had reached a settlement in a lawsuit accusing the firm's discontinued heartburn medicine, Zantac, of causing ...